Arcadia Biosciences, Inc.
RKDA
$1.12
$0.076.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.73% | 12.29% | 23.81% | 20.65% | 9.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.73% | 12.29% | 23.81% | 20.65% | 9.60% |
| Cost of Revenue | 8.60% | 40.16% | 64.91% | 52.66% | 10.97% |
| Gross Profit | -19.87% | -13.22% | -10.11% | -6.72% | 7.85% |
| SG&A Expenses | -27.41% | -6.79% | 5.52% | 21.16% | -0.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.17% | 2.68% | 16.90% | 27.64% | 1.81% |
| Operating Income | 29.62% | 4.37% | -11.80% | -33.35% | 2.87% |
| Income Before Tax | 45.89% | -595.03% | -3,806.08% | -167.73% | 39.59% |
| Income Tax Expenses | 0.00% | 14.29% | 14.29% | 0.00% | 0.00% |
| Earnings from Continuing Operations | 45.81% | -589.47% | -3,664.89% | -168.93% | 39.54% |
| Earnings from Discontinued Operations | -- | 99.47% | 93.07% | 84.70% | 60.25% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 66.77% | 13.04% | -11.10% | 71.28% | 49.66% |
| EBIT | 29.62% | 4.37% | -11.80% | -33.35% | 2.87% |
| EBITDA | 28.98% | 2.83% | -15.42% | -38.89% | 0.62% |
| EPS Basic | 66.94% | 13.28% | -10.71% | 71.33% | 63.75% |
| Normalized Basic EPS | 37.62% | -71.59% | -147.65% | -544.28% | 33.50% |
| EPS Diluted | 69.38% | 21.40% | -1.66% | 62.63% | 60.57% |
| Normalized Diluted EPS | 63.94% | -56.91% | -164.92% | -458.40% | 43.57% |
| Average Basic Shares Outstanding | 0.35% | 0.28% | 0.30% | 0.30% | 10.30% |
| Average Diluted Shares Outstanding | -7.68% | -7.74% | -7.79% | 33.67% | 47.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |